Ozempic is made by Novo Nordisk, a pharmaceutical company headquartered in Bagsvaerd, Denmark. Novo Nordisk also makes Wegovy, which contains the same drug at doses approved for weight management. The two products are not made by Novartis, a separate company that is sometimes confused with the name.
Quick Answer
Novo Nordisk manufactures Ozempic and Wegovy. Both contain semaglutide, a GLP-1 receptor agonist. Ozempic is approved for type 2 diabetes, and Wegovy is approved for chronic weight management. Novo Nordisk has worked on this class of drugs for more than two decades and produces semaglutide using engineered yeast.
Who Is the Manufacturer of Ozempic?
The maker of Ozempic is Novo Nordisk A/S, a Danish company founded in 1923. Its global headquarters sits in Bagsvaerd, a suburb of Copenhagen. Novo Nordisk has long focused on diabetes care and metabolic disease, and it manufactures both Ozempic and Wegovy, along with insulin products and the earlier GLP-1 drugs Victoza and Saxenda.
A frequent mix-up is "Novartis Ozempic." Novartis is a different Swiss pharmaceutical company and does not make Ozempic. The maker is Novo Nordisk.
What Are the Active Ingredients in Ozempic?
The single active ingredient in Ozempic is semaglutide. It is a glucagon-like peptide-1 (GLP-1) receptor agonist, a molecule that mimics a natural gut hormone the body releases after eating. By acting on GLP-1 receptors, it prompts insulin release when blood sugar is high, slows stomach emptying, and reduces appetite.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →The inactive ingredients listed on the FDA label include disodium phosphate dihydrate, propylene glycol, phenol, and water for injection. These stabilize and preserve the solution. Wegovy uses the active-ingredient equivalence, semaglutide, at higher approved doses for weight loss.
How Is Ozempic Made?
Semaglutide is produced through recombinant DNA technology rather than extracted from a natural source. In simple terms, Novo Nordisk inserts the genetic instructions for the peptide backbone into yeast cells, which then grow and produce the base peptide through fermentation. After fermentation, the peptide is purified and chemically modified by attaching a fatty acid chain. That modification is what lets semaglutide last about a week in the body, which is why Ozempic is a once-weekly injection.
This combination of biological fermentation and chemical synthesis is typical of how modern GLP-1 drugs are manufactured. The process requires large, tightly controlled facilities, which is one reason supply has been a recurring constraint for the whole drug class.
How Are GLP-1 Drugs Manufactured in General?
GLP-1 receptor agonists share a broad manufacturing pattern. The peptide is built either by recombinant expression in cells or by solid-phase peptide synthesis, then purified to pharmaceutical grade, modified for stability, formulated into a sterile injectable, and filled into pens or vials under sterile conditions. Different manufacturers use different methods. Eli Lilly makes tirzepatide for Mounjaro and Zepbound, and Novo Nordisk makes liraglutide and semaglutide. Each company controls its own supply chain.
How Long Has Semaglutide Been Around?
Novo Nordisk's GLP-1 research stretches back to the early 2000s, beginning with liraglutide, which became Victoza for diabetes and later Saxenda for weight management. Semaglutide built on that work. The FDA first approved semaglutide as Ozempic for type 2 diabetes in 2017. The higher-dose version, Wegovy, was approved for chronic weight management in 2021. An oral form, Rybelsus, was also approved for diabetes. So the injectable semaglutide molecule has been on the US market since 2017.
Comparison Table: Novo Nordisk GLP-1 Products
| Brand | Active ingredient | Approved use | Maker |
|---|---|---|---|
| Ozempic | Semaglutide | Type 2 diabetes | Novo Nordisk |
| Wegovy | Semaglutide | Weight management | Novo Nordisk |
| Rybelsus | Semaglutide (oral) | Type 2 diabetes | Novo Nordisk |
| Victoza | Liraglutide | Type 2 diabetes | Novo Nordisk |
| Saxenda | Liraglutide | Weight management | Novo Nordisk |
What About Compounded Semaglutide?
When brand-name supply is constrained, some patients access semaglutide through compounding pharmacies that prepare the medication under a prescription from a licensed provider. FormBlends works with licensed providers and pharmacies to offer compounded semaglutide for eligible patients, and the provider comparison tool lets you weigh options side by side. Compounded products are prepared by pharmacies rather than the brand manufacturer.
FAQs
Is Ozempic made by Novo Nordisk? Yes. Novo Nordisk makes both Ozempic and Wegovy.
Is Ozempic made by Novartis? No. Novartis is a separate company. Ozempic is made by Novo Nordisk.
Where is Novo Nordisk headquartered? In Bagsvaerd, Denmark, near Copenhagen.
Who makes Wegovy? Novo Nordisk makes Wegovy, which contains semaglutide at doses approved for weight loss.
What is the main ingredient in Ozempic? Semaglutide, a GLP-1 receptor agonist.
How is semaglutide produced? Through recombinant fermentation in yeast followed by chemical modification to extend how long it lasts in the body.
How long has Ozempic been available? Semaglutide was first approved as Ozempic for diabetes in 2017.
Does Novo Nordisk also make insulin? Yes. Insulin has been a core part of the company's portfolio for decades.
Sources
- https://www.novonordisk.com/about/contact-us.html
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209637s011lbl.pdf
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →